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The unusual a-amino, b-hydroxy acid MeBmt is a key structural feature of cyclosporin A, an important
naturally occurring immunosuppressant and antiviral agent. We present a convergent synthesis of
MeBmt which relies on new aspects of dynamic kinetic resolution (DKR) to establish simultaneously the
chirality at C(2) and C(3). We also show that this route is applicable to the synthesis of other derivatives.The a-amino-b-hydroxy unit is a familiar structural motif in
many important natural products, notably the proteinogenic
amino-acids serine and threonine, glycosphingolipids1 and
more complex structures such as the polyoxins.2 We were
particularly interested in the cyclic undecapeptide cyclosporin A
(CsA) 1, which contains the unusual amino acid [(2S,3R,4R,6E)-
3-hydroxy-4-methyl-2-(methylamino)-6-octenoic acid] (MeBmt
2) at position 1, shown in Fig. 1.
While CsA 1, rst attracted attention as a valuable immuno-
suppressant3 used especially following transplant surgery, it
was later found to have potent antiviral activity, notably against
hepatitis C virus (HCV) via its inhibition of the proline cis–trans
isomerase, cyclophilin A.4–6 Synthetic modication can
uncouple the antiviral eﬀects from the immunosuppressive
eﬀects,7,8 thus Debio-025 (Alisporivir), a CsA analogue modied
at positions 3 and 4, retains excellent activity vs. HCV (IC50 ¼ 30mt 2.
xford, OX1 3QU, UK
ent of Chemistry, University of Liverpool,
iv.ac.uk
of Diabetes and Digestive and Kidney
enter Drive, Bethesda, Maryland 20892,
ESI) available: Experimental details and
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39nM) and is essentially non-immunosuppressive.9 Additionally,
reported analogues of 1 modied at the MeBmt residue also
show antiviral activity while being essentially inactive as
immunosuppressants.7 Previous syntheses of 2 were too lengthy
and linear to facilitate a medicinal chemistry campaign of CsA
around 2.10–13 We therefore sought to develop a short eﬀective
synthesis of 2, which would readily permit the synthesis of
position 1 analogues of CsA without relying on partial synthesis.
Thus, our retrosynthesis of MeBmt 2 is shown in Scheme 1, it
relies on the syn-selective dynamic kinetic resolution (DKR) of
a b-ketoester precursor 3, which is in turn accessible via
a crossed Claisen condensation14 of an activated form of
carboxylic acid 4 with protected sarcosine ester 5.
Several groups have eﬀected DKR under catalytic asymmetric
transfer hydrogenation (ATH)15 conditions, the stereochemical
outcome is dependent on substrate structure. The synthesis of
b-hydroxy amino acid derivatives via ATH DKR is usually
undertaken via reduction from the prerequisite b-keto methyl
ester and the stereochemical outcome tends to the 2,3-anti-
product.16,17 This anti diastereoselectivity is proposed to be the
product of intramolecular hydrogen bonding.18 In contrast, g-
aryl-N-Me substrates underwent ATH DKR to give the desired
syn-products,19 though this had not been demonstrated with g-
alkyl substrates. We therefore set out to study these ATH-DKR
conditions, initially on a model isobutyryl substrate 6a, and
we now report our ndings, leading eventually to a concise
synthesis of MeBmt.
Compound 6a (Scheme 2) was prepared by a crossed Claisen
condensation between isobutyryl chloride and sarcosineScheme 1 Proposed disconnections in the synthesis of MeBmt. R1/2 ¼
protecting groups.
This journal is © The Royal Society of Chemistry 2019
Fig. 2 (A) Proposed intramolecular H-bonding accounting for the
anti-reduction of 6b18 (B) removing the H-bond leads to a completely
unreactive enol tautomer; (C) restoring an intra-H bond via an anilide.
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View Article Onlinederivative 7a (see ESI†); alternatively, using the corresponding
glycine ester 7b, 6b was readily obtained.14
Branching of the terminal alkyl substituent in 6a/6b has
been shown to improve stereoselectivity in ATH DKR of similar
substrates18 thus 6a/6b are good models for MeBmt. Substrate
6b was reduced eﬃciently via ATH DKR to the (2R,3R)-anti
product 8b (Table 1), however under these conditions the N-Me
substrate 6a, which was isolated almost entirely as the enol
tautomer (>95%, NMR), was unreactive towards ATH DKR.
Attempted optimisation of the ATH DKR step with increased
catalyst loading, elevated temperatures, and replacement of N-
benzoyl with other N-protecting groups (viz. CBz (6c)) and
alternative ATH DKR conditions16,20,21 led to the same result. In
contrast, related g-aryl-b-keto esters bearing an N-Me group are
reported to be eﬃciently reduced.19
We considered that the previously proposed intramolecular
hydrogen bonding18 (Fig. 2A and B) of 6b could also be
responsible for the reactivity of the compounds in general
through stabilisation or activation of the keto tautomer. The
successful syn-reduction of a g-aryl-N-Me, examples is, we
believe, largely due to the great preference for the keto tautomer
in such examples.
In contrast, our earlier g-alkyl-N-Me, substrate 6a existed
almost entirely as the enol tautomer (>95 : 5 enol) by 1H NMR.
We therefore proposed that a favourable intramolecular H-bond
could be reintroduced by employing an anilide rather than an
ester, in a substrate such as 9, Fig. 2C, ensuring a signicant
percentage of the necessary keto tautomer shown, indeed b-keto
anilides have been utilized in ATH DKR previously though not
in this context.22 Thus, the anilides were prepared according to
Scheme 3.
Thioesters such as 11 are excellent nucleophiles in the
crossed Claisen condensation with N-acyl benzotriazoles (10b)
and deliver thioesters in very good yield other than FMOC
derivative 12b which underwent base catalysed degradation.23
Finally, Ag+-catalysed aminolysis of the thioesters 12a–c deliv-
ered the desired anilides 9, 13 and 14 in high yield. The anilides
were isolated with a more favourable keto : enol ratio of
30 : 70 depending on R2 (determined by NMR in CDCl3).
Accordingly, incorporation of the anilide in the isobutyryl
series both re-establishes reactivity and reverses the original
anti diastereoselectivity, delivering the syn product 15, although
in low isolated yield (entries 4–6, Table 1). Other N-substituents,
viz. Z, entry 5, and Fmoc, entry 6, were also compatible with
these conditions, though Fmoc proceeds with much lower
yields in the preceding crossed-Claisen step, presumably due toScheme 2 Synthesis of a-acylamino-b-keto-esters and ATH DKR
discrepancy. (i) TiCl4, Bu3N, N-Me imidazole, CH2Cl2, 40 C; (ii)
HCO2Na, TBAI, CH2Cl2/H2O; 3% Ru(p-cymene)[(R,R)-TsDPEN], 20 C,
20 h. Isolated yields are shown.
This journal is © The Royal Society of Chemistry 2019decomposition under basic conditions. To permit a practical
transformation, we screened reaction conditions and a number
of commercially available catalysts and ligands to increase yield
and stereoselectivity17,24–28 (see ESI†). The most eﬃcient proved
to be the tethered catalyst described by Wills et al.; entry 7 and
illustrated in Table 1 B, this delivered a 64% isolated yield of
syn-17 aer 40 h, in >95 : 5 dr and >99 : 1 er with full
consumption of starting material. The full restoration of DKR
reaction with just 25–30% keto tautomer in the precursor is
emphasized.
g-Alkyl-b-hydroxy anilide 17 was crystallised in a form suit-
able for single crystal X-ray structure determination, conrming
the absolute conguration; shown in Table 1. Replacement of
the anilide with benzylamide did not permit ATH DKR,
presumably because of the lower acidity of the resultant NH.
With the DKR step optimized for the model substrate, we pro-
ceeded to complete the synthesis of MeBmt 2, Scheme 4. Based
on a method originally reported by Rich et al.29 starting from
()-3-buten-2-ol 18, a Johnson–Claisen rearrangement followed
by transformation of the crude ethyl ester gave (S,R)-phenyl-
glycinol amide 19, which could be separated from its (S,S) dia-
stereomer by gradient column chromatography in multigram
amounts. The amide was quantitatively hydrolysed under acid
catalysis aided by neighbouring OH-group participation to
aﬀord carboxylic acid (2R)-20. Conversion to the activated N-
acyl-benzotriazolyl (Bt) electrophile30 (2R)-21 (stable at room
temperature in air), followed by a crossed Claisen condensation
with sarcosine derivative 22 (see ESI†), aﬀorded enol thioester
23, which was converted to b-keto-anilide 24 in excellent yieldScheme 3 Synthesis of g-alkyl-b-keto-anilides (i) 1H-benzotriazole,
SOCl2, DCM, 20 C (ii) MgBr2$OEt2,
iPrNEt2, DCM, 0–20 C, 16 h (iii)
PhNH2, AgCO2CF3, THF, 20 C, 16 h. Isolated yields are shown.
RSC Adv., 2019, 9, 40336–40339 | 40337
Table 1 Summary of ATHDKR reactivity across key substrates. A X-ray crystal structure of (2S, 3R)-17. B ATH catalyst [(R,R)-Teth-TsDpen] used in
entry 7
Entry Cmpd R1 R2 R3 Keto : enol Product
Isolated yield
(%) dra erb
1 6b H Bz OMe >95 : 5 8b 82 15 : 85 ND
2 6a Me Bz OMe >5 : 95 — NR ND ND
3 6c Me CBz OMe >5 : 95 — NR ND ND
4 13 Me Bz NHPh 28 : 72 15 4 >95 : 5 ND
5 14 Me FMOC NHPh 25 : 75 16 18 >95 : 5 >99 : 1
6 9 Me CBz NHPh 30 : 70 17 13 >95 : 5 >99 : 1
7c 9 Me CBz NHPh 30 : 70 17 64 >95 : 5 >99 : 1
a Syn : anti ratio (1H NMR). b Ratio of (2S,3R) : (2R,3S) enantiomers. c 10% [(R,R)-Teth-TsDpen], 40 h, 20 C.
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View Article Onlineunder mild conditions. Syn selective ATH DKR aﬀorded b-
hydroxy-amide 25, without observable epimerization at C4
(judged by 1H NMR). Base hydrolysis of 25 led to universal
deprotection,31 yielding MeBmt 2 without any detectable race-
mization (1H NMR).
Finally, in Scheme 4 we demonstrate that the route is
applicable to the synthesis of several g-alkyl-a-N-Me derivatives
including model isopropyl examples 17 and 26, MeBmt
precursor 25 and isomer 27. Structurally novel cycloalkyl
examples 28–31 were also synthesized starting from their
constituent carboxylic acids (see ESI†). Absolute stereochem-
istry is controlled by using the opposite enantiomer of catalyst,
in all cases the major and minor diastereomers could be sepa-
rated by column chromatography. From this small set, it can beScheme 4 Synthesis of MeBmt via ATH DKR and demonstration of sub
procedures. Isolated yield following aqueous workup and column chrom
expressed as major : minor in puriﬁed major diastereomer. Absolute ste
40338 | RSC Adv., 2019, 9, 40336–40339seen that stereoselectivity increases as the steric bulk of the side
chain increases across the series. Interestingly, a match/
mismatch eﬀect in the reduction of 24 with (S,S)-Teth-TsDPEN
was observed: reduction from the re-face of the molecule was
slower than reduction from the si-face (cf. 25 and 27), judged by
TLC, which was also reected in the isolated yields and the
diastereoselectivity. This is expected to be a consequence of the
increased steric bulk of the (4R)-butenyl group in substrate 24
producing facial discrepancies in catalyst approach.
In conclusion, through analysis of intramolecular hydrogen
bonding, we have expanded the scope of the ATH DKR reaction,
giving access to biologically relevant g-alkyl-b-hydroxy-a-Me-
amino acids from readily accessible b-keto precursors. This
was accomplished by switching from b-keto-esters to b-keto-strate scope. Analogues were synthesized according to the optimised
atography are shown, dr is expressed as syn : anti in crude product, er is
reochemistry in products is dependent on catalyst conﬁguration.
This journal is © The Royal Society of Chemistry 2019
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View Article Onlineanilides, which was suﬃcient to restore reactivity and reverse
the original anti diastereoselectivity, delivering the syn prod-
ucts. Accordingly, we demonstrated a synthesis of MeBmt, 2 in
ve linear steps from precursor carboxylic acid (2R)-20 and have
further shown that this route is also applicable for the synthesis
of alternative g-alkyl derivatives. The route is reasonably short,
while also being modular and exible in terms of side chain
choice and absolute stereochemical outcome.
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